Stem Cell Therapy Market by Type (Allogeneic, Autologous), Therapeutic Application (Musculoskeletal, Wound & Injury, CVD, Surgery, and aGVHD), Cell Source (Adipose tissue, Bone Marrow, Neural, Embryo/Cord Blood derived, iPSCs) - Global Forecasts to 2021

The global stem cell therapy market is estimated to reach USD 145.8 Million by 2021, growing at a CAGR of 11.0% during the forecast period. Growing awareness related to the therapeutic potency of stem cells in disease management, development of advanced genome-based cell analysis techniques, increasing public-private investments for stem cell research and development, identification of new stem cell lines, and developments in infrastructure for stem cell banking and processing are some key factors driving the growth of this market. Furthermore, countries such as Japan, South Korea, and China offer new growth opportunities for market players. On the other hand, unclear regulatory guidelines related to the development & commercialization of stem cell therapy products and socio-ethical issues related to the adoption of ESCs in disease treatment are the major factors restraining the market growth.

The North American region is expected to command the largest share of the stem cell therapy market in 2016. Factors such as rising public awareness related to the therapeutic potency of stem cells in disease therapy, growing number of clinical trials that aim to evaluate therapeutic potential of stem cell-based products, increasing public-private funding & research grants for developing safe and effective stem cell therapy products, and the growing patient base for target diseases are driving the growth of the market in this region.

As of 2015, Osiris Therapeutics, Inc. (U.S.) led the global stem cell therapy market. Over the past three years, the company has adopted product launches as well as partnerships and agreements as its key growth strategies to ensure its dominance in market. MEDIPOST Co., Ltd. (South Korea), Anterogen Co., Ltd. (South Korea), Pharmicell Co., Ltd. (South Korea), Holostem Terapie Avanzate S.r.l. (Italy), JCR Pharmaceuticals Co., Ltd. (Japan), NuVasive, Inc. (U.S.), RTI Surgical, Inc. (U.S.), and AlloSource (U.S.) are some of the other key players in this market.

Target Audience

• Stem Cell Therapeutic Product Manufacturing Companies
• Healthcare Service Providers (including Hospitals and Diagnostic Centers)
• Pharmaceutical Product Manufacturing Companies
• National and Regional Research Boards and Organizations
• Research and Development (R&D) Companies
• Clinical Research Organizations (CROs)
• Research Laboratories and Academic Institutes
• Market Research and Consulting Firms
• Stem Cell Associations and Organizations

To know about the assumptions considered for the study, download the pdf brochure

Scope of the report

This research report categorizes the global market into the following segments:

Stem Cell Therapy Market, by Type

• Allogeneic Stem Cell Therapy, by Application
• Musculoskeletal disorders
• Wounds and Injuries
• Surgeries
• acute Graft-Versus-Host Disease (aGVHD)
• Other Applications
• Allogeneic Stem Cell Therapy, by Application
• Wounds and Injuries
• Cardiovascular Diseases
• Gastrointestinal Diseases
• Other Applications

Stem Cell Therapy Market, by Therapeutic Application

• Musculoskeletal disorders
• Wounds and Injuries
• Cardiovascular Diseases
• Surgeries
• Gastrointestinal Diseases
• Other Therapeutic Applications

Stem Cell Therapy Market, by Cell Source

• Adipose Tissue-derived Mesenchymal Stem Cells
• Bone Marrow-derived Mesenchymal Stem Cells
• Cord Blood/Embryonic Stem Cells
• Other Cell Sources

Stem Cell Therapy Market, by Region

• North America
• Europe
• Asia-Pacific
• Rest of the World

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for market report:

Product Analysis

• Product matrix which gives a detailed comparison of the product portfolios of the top 5 companies

Company Information

• Detailed analysis and profiling of additional market players (Up to 5)

Table of Contents

1 Introduction (Page No. - 15)
    1.1 Objectives of the Study
    1.2 Market Definition
    1.3 Market Scope
           1.3.1 Markets Covered
           1.3.2 Geographic Scope
           1.3.3 Years Considered for the Study
    1.4 Currency
    1.5 Limitations
    1.6 Stakeholders

2 Research Methodology (Page No. - 19)
    2.1 Research Data
           2.1.1 Secondary Data
                    2.1.1.1 Key Data From Secondary Sources
           2.1.2 Primary Data
                    2.1.2.1 Key Data From Primary Sources
                    2.1.2.2 Breakdown of Primaries
    2.2 Market Size Estimation
           2.2.1 Bottom-Up Approach
           2.2.2 Top-Down Approach
    2.3 Market Breakdown and Data Triangulation
    2.4 Research Assumptions

3 Executive Summary (Page No. - 26)
    3.1 Introduction
    3.2 Conclusion

4 Premium Insights (Page No. - 30)
    4.1 Market Overview
    4.2 Regional Analysis: Market, By Type, 2016 vs 2021 (USD Million)
    4.3 Global Market, By Therapeutic Application, 2016–2021 (USD Million)
    4.4 Regional Analysis: Market, By Cell Source, 2016 vs 2021 (USD Million)

5 Market Overview (Page No. - 34)
    5.1 Introduction
    5.2 Market Dynamics
           5.2.1 Market Growth Drivers
                    5.2.1.1 Growing Awareness Related to the Therapeutic Potency of Stem Cells in Effective Disease Management
                    5.2.1.2 Development of Advanced Genome-Based Cell Analysis Techniques
                    5.2.1.3 Increasing Public-Private Investments for the Development of Stem Cell Therapies
                    5.2.1.4 Development in Infrastructure Related to Stem Cell Banking and Processing
           5.2.2 Market Restraints
                    5.2.2.1 Unclear Regulatory Guidelines for Product Development & Commercialization
                    5.2.2.2 Socio-Ethical Issues Related to the Use of Escs in Disease Treatment
           5.2.3 Market Growth Opportunities
                    5.2.3.1 Supportive Regulations Across Developing Countries
                    5.2.3.2 Emergence of Ipscs as an Effective Alternative to Escs
           5.2.4 Market Challenges
                    5.2.4.1 Technical Limitations Related to Production Scale-Up
    5.3 Regulatory Landscape
           5.3.1 North America
           5.3.2 Europe
           5.3.3 Asia-Pacific
           5.3.4 Rest of the World

6 Industry Insights (Page No. - 46)
    6.1 Introduction
    6.2 Supply Chain Analysis
           6.2.1 Key Stakeholders
           6.2.2 Key Influencers
    6.3 Pipeline Analysis
           6.3.1 Pipeline Analysis: Based on Phase of Clinical Study
           6.3.2 Pipeline Analysis: Based on Type
           6.3.3 Pipeline Analysis: Based on the Cell Line Used

7 Global Stem Cell Therapy Market, By Type (Page No. - 52)
    7.1 Introduction
    7.2 Allogeneic Stem Cell Therapy Market, By Application
           7.2.1 Musculoskeletal Disorders
           7.2.2 Wounds and Injuries
           7.2.3 Surgeries
           7.2.4 Acute Graft-Versus-Host Disease (AGVHD)
           7.2.5 Other Applications
    7.3 Autologous Stem Cell Therapy Market, By Application
           7.3.1 Wounds and Injuries
           7.3.2 Cardiovascular Diseases
           7.3.3 Gastrointestinal Diseases
           7.3.4 Other Applications

8 Global Stem Cell Therapy Market, By Therapeutic Application (Page No. - 65)
    8.1 Introduction
    8.2 Musculoskeletal Disorders
    8.3 Wounds and Injuries
    8.4 Cardiovascular Diseases
    8.5 Surgeries
    8.6 Gastrointestinal Diseases
    8.7 Other Applications

9 Global Stem Cell Therapy Market, By Cell Source (Page No. - 73)
    9.1 Introduction
    9.2 Adipose Tissue-Derived Mesenchymal Stem Cells
    9.3 Bone Marrow-Derived Mesenchymal Stem Cells
    9.4 Cord Blood/Embryonic Stem Cells
    9.5 Other Cell Sources

10 Stem Cell Therapy Market, By Region (Page No. - 78)
     10.1 Introduction
     10.2 North America
     10.3 Europe
     10.4 Asia-Pacific
     10.5 Rest of the World (RoW)

11 Competitive Landscape (Page No. - 92)
     11.1 Overview
     11.2 Market Ranking
     11.3 Strategic Benchmarking
             11.3.1 Product Development and Commercialization
     11.4 Competitive Scenario
     11.5 Recent Developments
             11.5.1 Product Launches and Approvals
             11.5.2 Expansions
             11.5.3 Agreements, Collaborations, and Partnerships

12 Company Profiles (Page No. - 98)
     12.1 Introduction
             12.1.1 Geographic Benchmarking
(Overview, Financials, Products & Services, Strategy, and Developments)*
     12.2 Osiris Therapeutics, Inc.
     12.3 Medipost Co., Ltd.
     12.4 Anterogen Co., Ltd.
     12.5 Pharmicell Co., Ltd.
     12.6 Holostem Terapie Avanzate Srl
     12.7 JCR Pharmaceuticals Co., Ltd.
     12.8 Nuvasive, Inc.
     12.9 RTI Surgical, Inc.
     12.10 Allosource

*Details on Overview, Financials, Product & Services, Strategy, and Developments Might Not Be Captured in Case of Unlisted Companies.

13 Appendix (Page No. - 113)
     13.1 Insights of Industry Experts
     13.2 Discussion Guide
     13.3 Knowledge Store: Marketsandmarkets’ Subscription Portal
     13.4 Introducing RT: Real-Time Market Intelligence
     13.5 Available Customizations
     13.6 Related Reports
     13.7 Author Details

List of Tables (60 Tables)

Table 1 Few of the Recently Launched Cell Analysis Products (2015-2017)
Table 2 North America: Regulatory Landscape for Stem Cell Therapy (As of 2016)
Table 3 Europe: Regulatory Landscape for Stem Cell Therapy (As of 2016)
Table 4 Asia-Pacific: Regulatory Landscape for Stem Cell Therapy (As of 2016)
Table 5 RoW: Regulatory Landscape for Stem Cell Therapy (As of 2016)
Table 6 Global Market Size, By Type, 2014-2021 (USD Million)
Table 7 Global Allogeneic Stem Cell Therapy Market Size, By Application, 2014-2021 (USD Million)
Table 8 Global Allogeneic Market Size, By Region, 2014-2021 (USD Million)
Table 9 Allogeneic Stem Cell Therapy Market Size for Musculoskeletal Disorders, By Region, 2014-2021 (USD Million)
Table 10 Allogeneic Market Size for Wounds and Injuries, By Region, 2014-2021 (USD Million)
Table 11 Allogeneic Stem Cell Therapy Market Size for Surgeries, By Region, 2014-2021 (USD Million)
Table 12 Allogeneic Market Size for Acute Graft-Versus-Host Disease, By Region, 2014-2021 (USD Million)
Table 13 Allogeneic Stem Cell Therapy Market Size for Other Applications, By Region, 2014-2021 (USD Million)
Table 14 Global Autologous Market Size, By Application, 2014-2021 (USD Million)
Table 15 Global Autologous Market Size, By Region, 2014-2021 (USD Million)
Table 16 Autologous Market for Wounds and Injuries, By Region, 2014-2021 (USD Million)
Table 17 Autologous Stem Cell Therapy Market Size for Cardiovascular Diseases, By Region, 2014-2021 (USD Million)
Table 18 Autologous Market Size for Gastrointestinal Diseases, By Region, 2014-2021 (USD Million)
Table 19 Autologous Market Size for Other Applications, By Region, 2014-2021 (USD Million)
Table 20 Global Market Size, By Therapeutic Application, 2014-2021 (USD Million)
Table 21 Market Size for Musculoskeletal Disorders, By Region, 2014-2021 (USD Million)
Table 22 Market Size for Wounds and Injuries, By Region, 2014-2021 (USD Million)
Table 23 Market Size for Cardiovascular Diseases, By Region, 2014-2021 (USD Million)
Table 24 Market Size for Surgeries, By Region, 2014-2021 (USD Million)
Table 25 Market Size for Gastrointestinal Diseases, By Region, 2014-2021 (USD Million)
Table 26 Market Size for Other Applications, By Region, 2014-2021 (USD Million)
Table 27 Global Market Size, By Cell Source, 2014-2021 (USD Million)
Table 28 Market Size for Adipose Tissue-Derived MSCS, By Region, 2014-2021 (USD Million)
Table 29 Market Size for Bone Marrow-Derived MSCS, By Region, 2014-2021 (USD Million)
Table 30 Market Size for Cord Blood/Embryonic Stem Cells, By Region, 2014-2021 (USD Million)
Table 31 Market Size for Other Cell Sources, By Region, 2014-2021 (USD Million)
Table 32 Market Size, By Region, 2014-2021 (USD Million)
Table 33 North America: Market Size, By Type, 2014-2021 (USD Million)
Table 34 North America: Market Size, By Therapeutic Applications, 2014-2021 (USD Million)
Table 35 North America: Market Size, By Cell Source, 2014-2021 (USD Million)
Table 36 Europe: Market Size, By Type, 2014-2021 (USD Million)
Table 37 Europe: Market Size, By Therapeutic Application, 2014-2021 (USD Million)
Table 38 Europe: Stem Cell Therapy Market Size, By Cell Source, 2014-2021 (USD Million)
Table 39 Asia-Pacific: Market Size, By Type, 2014-2021 (USD Million)
Table 40 Asia-Pacific: Market Size, By Therapeutic Application, 2014-2021 (USD Million)
Table 41 Asia-Pacific: Stem Cell Therapy Market Size, By Cell Source, 2014-2021 (USD Million)
Table 42 RoW: Market Size, By Type, 2014-2021 (USD Million)
Table 43 RoW: Market Size, By Therapeutic Application, 2014-2021 (USD Million)
Table 44 RoW: Stem Cell Therapy Market Size, By Cell Source, 2014-2021 (USD Million)
Table 45 Top Product Launches and Approvals (2013–2016)
Table 46 Top Expansions (2013 – 2016)
Table 47 Top Agreements, Collaborations, and Partnerships (2013-2016)
Table 48 Osiris Therapeutics, Inc.: Products Offered
Table 49 Osiris Therapeutics, Inc.: Product Pipeline
Table 50 Medipost Co., Ltd.: Products Offered
Table 51 Medipost Co., Ltd.: Product Pipeline
Table 52 Anterogen Co., Ltd.: Products Offered
Table 53 Anterogen Co., Ltd.: Product Pipeline
Table 54 Pharmicell Co., Ltd.: Products Offered
Table 55 Pharmicell Co., Ltd.: Product Pipeline
Table 56 Holostem Terapie Avanzate Srl: Products Offered
Table 57 JCR Pharmaceuticals Co., Ltd.: Products Offered
Table 58 Nuvasive, Inc.: Products Offered
Table 59 RTI Surgical, Inc.: Products Offered
Table 60 Allosource: Products Offered

List of Figures (37 Figures)

Figure 1 Research Design
Figure 2 Bottom-Up Approach
Figure 3 Top-Down Approach
Figure 4 Data Triangulation
Figure 5 Assumptions for the Study
Figure 6 Allogeneic Stem Cell Therapy Dominates the Market in 2016
Figure 7 Musculoskeletal Disorders Commands the Largest Share of the Market in 2016
Figure 8 Adipose Tissue-Derived MSCS Will Continue to Dominate the Market Till 2021
Figure 9 Market Share, By Region
Figure 10 Emerging Countries Offer High-Growth Opportunities to Players in the Market
Figure 11 Allogeneic Stem Cell Therapy to Dominate the Global Market During Forecast Period
Figure 12 Musculoskelatal Disorders Segment to Dominate the Global Market During Forecast Period
Figure 13 Adipose Tissue-Derived Cell Source Segment to Dominate the Market During Forecast Period
Figure 14 Growing Public Awareness Related to Therapeutic Potency of Stem Cells is Augmenting the Market Growth During the Study Period
Figure 15 Market Players Prefer Both Direct & Indirect Distribution Strategies for Stem Cell Therapy Products Across Major Geographies
Figure 16 Majority of Stem Cell Therapy Candidate Products are in Preclinical Phase, Followed By Phase 1 & Phase 1/2
Figure 17 Allogeneic Stem Cell Therapy Pipeline Products Account for A Larger Share of the Overall Stem Cell Therapy Products Under Development
Figure 18 Allogeneic Stem Cell Therapy Pipeline Products: Based on Study Phases
Figure 19 Autologous Stem Cell Therapy Pipeline Products: Based on Study Phases
Figure 20 Bone Marrow-Derived Mesenchymal Stem Cells are Preferred for Stem Cell Therapy Development
Figure 21 Allogeneic Stem Cell Therapy to Dominate the Global Stem Cell Therapy Market Till 2021
Figure 22 Musculoskelatal Disorders to Dominate the Allogeneic Market Till 2021
Figure 23 Wounds and Injuries Market to Dominate the Autologous Stem Cell Therapy Market Till 2021
Figure 24 Musculoskelatal Disorders Segment to Dominate Global Market Till 2021
Figure 25 Adipose Tissue-Derived Mesenchymal Stem Cells to Dominate the Global Stem Cell Therapy Market Till 2021
Figure 26 North America: Market Snapshot
Figure 27 Europe: Market Snapshot
Figure 28 Asia Pacific: Market Snapshot
Figure 29 RoW: Market Snapshot
Figure 30 Global Market Ranking (2015)
Figure 31 Product Development and Commercialization: the Key Growth Strategy Adopted By Stem Cell Therapy Market Players (2013-2016)
Figure 32 Product Launches and Enhancements: Key Strategy Adopted By Majority of Key Players During Study Period
Figure 33 Geographic Revenue Mix of the Top Five Players (2015)
Figure 34 Medipost Co., Ltd.: Company Snapshot (2015)
Figure 35 JCR Pharmaceuticals Co., Ltd.: Company Snapshot (2015)
Figure 36 Nuvasive, Inc.: Company Snapshot (2015)
Figure 37 RTI Surgical, Inc.: Company Snapshot (2015)

The global stem cell therapy market is expected to reach USD 145.8 Million by 2021, growing at a CAGR of 11.0% during the forecast period. Factors such as the growing awareness related to the therapeutic potency of stem cells in disease management, ongoing development of advanced genome-based cell analysis techniques, increasing public-private investments for stem cell research and product development, identification of new stem cell lines, and developments in infrastructure for stem cell banking and processing are driving the growth of the global market. However, factors such as unclear regulatory guidelines related to the development & commercialization of stem cell therapy products and socio-ethical issues related to the adoption of ESCs in disease treatment are restraining the growth of this market. In addition to this, technical limitations related to production scale-up pose a key challenge for players operating in this market.

On the basis of type, the global market is divided into two major categories, namely, allogeneic stem cell therapy and autologous stem cell therapy. On the basis of application, the allogeneic stem cell therapy market is further divided into musculoskeletal disorders, wounds and injuries, surgeries, acute Graft-Versus-Host Disease (aGVHD), and other applications. On the basis of application, the autologous stem cell therapy market is categorized into wounds and injuries, cardiovascular diseases, gastrointestinal diseases, and other applications. The allogenic stem cell therapy segment is expected to grow at the highest CAGR during the forecast period, owing to the rising commercialization of allogeneic stem cell therapy products, wider therapeutic applications of allogeneic stem cells, easy production scale-up process, and growing number of clinical trials related to allogeneic stem cell therapies.

On the basis of region, this market is classified into North America, Europe, Asia-Pacific, and the Rest of the World. In 2016, the global market is expected to be dominated by North America. Also, this region is expected to be the fastest-growing region during the forecast period. Factors such as growing awareness related to the therapeutic potency of stem cells, increasing number of clinical trials for stem cell-based products, and increasing public-private funding & research grants are driving the growth of this market in the North American region.

New product launches and approvals are the key growth strategies adopted by major players to strengthen their positions in the global market. Moreover, strategies such as expansions as well as partnerships and agreements were also adopted by several market players to expand their R&D capabilities and geographic presence in the global market.

As of 2015, Osiris Therapeutics, Inc. (U.S.), MEDIPOST Co., Ltd. (South Korea), Anterogen Co., Ltd. (South Korea), Pharmicell Co., Ltd. (South Korea), Holostem Terapie Avanzate S.r.l. (Italy), JCR Pharmaceuticals Co., Ltd. (Japan), NuVasive, Inc. (U.S.), RTI Surgical, Inc. (U.S.), and AlloSource (U.S.) were some of the key players operating in the global market.

To speak to our analyst for a discussion on the above findings, click Speak to Analyst